Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Metrics to compare | JUBN | Peers Peers - average of corresponding metrics from companies closely matching JUBN: ANURAS, PIIND, AARTIIND, COROMANDEL, CHEMCON | Sector Sector - Average of metrics from a broad group of related Basic Materials sector companies | Relationship RelationshipJUBNPeersSector |
---|---|---|---|---|
P/E Ratio | 72.1x | 41.1x | 0.1x | |
PEG Ratio | −1.86 | 0.06 | 0.00 | |
Price/Book | 4.6x | 3.4x | 1.6x | |
Price / LTM Sales | 3.1x | 4.0x | 1.3x | |
Upside (Analyst Target) | 6.9% | 8.8% | 24.1% | |
Fair Value Upside | Unlock | −9.2% | 0.4% | Unlock |